The climacteric syndrome is a complex condition characterized by a set of symptoms and degenerative changes that ensue due to the decline in production of sex steroids by the ovaries. Hence, there is a need for safe methods for the short-and long-term management of postmenopausal women. Hormone-replacement therapy (HRT) is widely used for the relief of menopausal symptoms and for the prevention of diseases linked to longterm hormonal deprivation. The use of HRT has increased rapidly in the past decade, but is currently a subject of debate because of the possible negative effects on the breast and on the cardiovascular system. Other molecules have been studied as alternatives to standard HRT to also relieve symptoms in women with contraindications to hormones or who refuse sex steroids for personal reasons. The aim of this article is to discuss the results of the principal studies performed in the past few years on the safety of HRT and of other climacteric therapies.
U S E N D O C R I N E D I S E A S E 2 0 0 7 cholesterol, and hypertension), and this might explain the failure of this trial in demonstrating overall cardiovascular benefits with HRT.
Bones
Osteoporosis is characterized by reduced bone mass that leads to reduced bone quality and resistance and, consequently, to an increased risk of fractures. Osteoporosis is a very common condition in postmenopausal women, causing significant morbidity and reduced quality of life.
Circulating estradiol has a protective effect on the bones, reducing skeletal remodeling through many mechanisms: reduction in activation of bone metabolic units; enhanced survival of osteoclasts; improved efficiency of gastrointestinal calcium absorption; and renal calcium conservation. Observational studies in which the treatment is started in the early postmenopausal period show a decreased risk of Alzheimer's disease with treatment. 12 In contrast to these results, the WHI Memory Study (WHIMS)
showed nearly a doubling of risk of all-cause dementia. 13 One explanation for this discrepancy is that late initiation of hormone therapy (after 65 years), as in the WHIMS, may not be effective in preventing neurodegeneration and may instead precipitate vascular dementia, whereas early use confers benefit. 2, 14 While the prevention of Alzheimer's disease with HRT is still to be established, it seems that the initiation of HRT in patients aged 65 or more may increase the risk of impaired cognitive function.
Breast Cancer
Breast cancer is the most common cancer in women in developed countries. Correlation between HRT use and breast-cancer risk has been studied in many epidemiological studies. A large meta-analysis published in 1997 indicated that the risk of breast cancer is raised in women using HRT and increases with increasing duration of use. 16 This excess risk is reduced after HRT cessation and disappears within five years. 16 Recently, the WHI study reported a 26% increase in the relative risk of breast cancer for combined estrogen-progestogen compared with a placebo. However, the parallel arm of the WHI study investigating the effect of the administration of estrogens alone showed no increase of breast cancer, with a trend toward a reduction of risk. 17 This study, along with the long-term analysis of the Nurse's Health Study, in general indicates that the impact of HRT on the incidence of breast cancer is limited and associated only with very long administrations. 18 In addition, recent trials call for new research to better understand the role of progestins, showing that-based on the compound-the risk of breast cancer changes.
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Endometrial Cancer
The majority of all endometrial malignancies occurs mostly in perimenopausal and early post-menopausal women. The pathogenesis is, in part, linked to prolonged and excessive exposure to endogenous or exogenous estrogens, not balanced by the cyclical production of progesterone. The risk of endometrial cancer is not clearly related to the dose but rather to the duration of unopposed estrogen exposure, as longterm administration correlates with a five-fold higher risk. 20 HRT with estrogen alone increases endometrial cancer risk, whatever the type and dose of estrogen and the route of administration. 20 Progesterone has a well-known anti-estrogenic effect on the endometrium. 21 The addition of a progestogen to the estrogen-replacement therapy is then mandatory to avoid the risk of endometrial cancer, contrasting the stimulation of the endometrium by estrogens. To this extent, in the presence of a progestin, endometrial-cancer risk is decreased either with cyclical or continuous HRT.
Cyclical regimens that include more than 10 days of progestogen exposure per month appear to provide maximum protection.
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Colorectal Cancer
Colorectal carcinoma is a leading cause of illness and death in developed countries, being the second most common cancer in women after breast cancer. 23 There is strong evidence to show that the incidence of colorectal carcinoma can be significantly reduced by HRT. A meta-analysis of 18 epidemiological studies of HRT and colorectal cancer showed a 20% reduction of colon-and rectal-cancer risk in women who had ever taken HRT compared with those had never taken HRT. 23 In addition, the WHI trial showed a significant reduction in colon-cancer risk in HRT users. The possible biological explanation of this reduction of risk includes the effect of sex steroids on bile-acid metabolism and direct effects on the colonic epithelium.
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Other Therapies
Other molecules have been studied as alternatives to standard replacement therapy with sex-steroid hormones.
Tibolone
Tibolone is a synthetic steroid that is rapidly converted to two metabolites
with estrogenic activity and to a third metabolite characterized by a mixed progestogenic/androgenic activity. 25 Tibolone controls hot flushes, sweating, and mood symptoms and, due to its androgenic component, is effective in improving libido.
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Cardiovascular System
Cardiovascular clinical outcomes from randomized controlled trials are not yet available. Surrogate end-point studies for arterial disease and venous thrombo-embolic disease are inconclusive with regard to benefit or risk. 29 
Bones
Randomized, controlled studies show that tibolone increases BMD and reduces risk of fracture. 30, 31 These beneficial effects are seen over long-term treatments (>10 years) and in both early and late post-menopausal women, as well as in women with established osteoporosis. 32 
Breast Cancer
The Million Women Study reported an increased risk of breast cancer in women treated with tibolone, although this was significantly lower than that seen with combined therapies with estrogens and progestins. 33 However, this study has many biases, including the likely selective prescription of tibolone to women at higher risk of breast cancer due to the assumption that this compound could be less active on the breast with respect to standard HRT.
The combined analysis of randomized clinical studies on tibolone indicates no increase in risk of breast cancer development compared with placebo.
Tibolone treatment is associated with a reduction of proliferation and a stimulation of apoptosis in normal breast cells, which is possibly attributable to the impact of this compound on the activity of estrogen-metabolizing breast enzymes. 34 Due to these findings, the administration of tibolone is currently under evaluation for the treatment of climacteric symptoms in breast cancer patients by the Livial Intervention Following Breast Cancer:
Efficacy, Recurrence, and Tolerability End-points trial. 34 
Endometrial Cancer
The metabolization of tibolone is tissue-selective and the conversion to the progestogenic metabolite is particularly active in the endometrium.
Investigation of endometrial histology in women treated with tibolone shows no hyperplasia and a high level of atrophic endometrium, indicating no proliferative effect of this molecule.
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Phyto-estrogens
Phyto-estrogens are biologically active compounds found in certain plants in high concentrations. They have a chemical structure similar to that of estradiol and the ability to bind to estrogen receptors exerting variable estrogenic and anti-estrogenic effects. 37 Many clinical studies have been conducted to assess the effects of phyto-estrogens on post-menopausal syndrome, but, while some studies report a modest benefit compared with placebo, others do not.
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Cardiovascular System
In vitro, genistein-a phyto-estrogenic molecule-stimulates the synthesis of nitric oxide from endothelial cells. 46 Clinical trials demonstrate that consuming 25-50g per day of soy protein is effective in reducing low-density lipoprotein cholesterol by approximately 4-8%, and the Framingham Offspring Study reported that a high intake of phyto-estrogens in post-menopausal women is associated with a
